Editorial Type:
Article Category: Research Article
 | 
Online Publication Date: 13 Jul 2020

Assessment of the Healing of Dental Implant Surgical Site Following Low-Level Laser Therapy Using Bioclinical Parameters: An Exploratory Study

MDS,
MDS,
MDS,
MDS,
MD,
MDS,
MDS, and
MDS
Page Range: 230 – 235
DOI: 10.1563/aaid-joi-D-18-00316
Save
Download PDF

The purpose of this study was to evaluate whether low-level laser therapy improves healing of the implant surgical site with clinical and biochemical parameters. Thirty patients with an edentulous space spanning a single tooth were selected. The patients were randomly allocated to 1 of 2 groups: control group and test group. The test group received laser energy at a power of 2 J/cm2 with a total of 4–6 J energy over each implant. Clinical parameters (implant stability quotient, probing index, modified sulcus bleeding index) and osteoprotegerin were assessed at baseline and follow-up intervals (2 weeks, 6 weeks, and 3 months). The test group showed significantly higher implant stability quotient than the control group at 2 weeks (57.93 ± 3.95 vs 35.67 ± 3.08; P < . 01) and 3 months (58.86 ± 3.75 vs 67.06 ± 3.78; P < . 01). A significant rise in osteoprotegerin levels of the test group (686.30 ± 125.36 pg/mL at baseline and 784.25 ± 108.30 pg/mL at 3 months; P < . 01) was seen contrary to significant decline in the control group (839.50 ± 249.08 pg/mL at baseline vs 415.30 ± 78.39 pg/mL at 3 months; P < . 01). Within the limitations of the study, the findings suggest that the healing of peri-implant hard and soft tissues may be enhanced with the use of low-level laser therapy as an explicit modality during the postoperative period.

Figures 1–3.
Figures 1–3.

Figure 1. Fotona's light walker dental laser system with R24 handpiece. Figure 2. Application of pulsed Nd:YAG laser beam of wavelength 1064 nm over the implant site in a mesial-distal direction. Figure 3. Ostell device showing implant stability quotient value measured during the follow-up


Figure 4.
Figure 4.

Plot showing osteoprotegerin levels at baseline, 2 weeks, 6 weeks, and 3 months in the control and test groups.


Contributor Notes

Corresponding author, e-mail: varp1812@gmail.com
  • Download PDF